Patent US2086571A successfully refreshed from Google Patents.
Patent US1997807A successfully refreshed from Google Patents.
Patent US4064007A successfully refreshed from Google Patents.
US4064007A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for obtaining an active product from mammalian macrophages
Assignee: Institut National de la Santé et de la Recherche Médicale
•
Filing: 1976-03-02
•
Granted: 1977-12-20
•
Expires: 1996-03-02
Abstract
Abstract Continuous cell lines of macrophages are provided by the in vitro action, on mammalian macrophages withdrawn in situ, of macrophage activating substances, which cause the removal by the macrophages of the other cells present in the cellular medium withdrawn. The macrophages thus isolated are then placed in a suitable culture medium, until the establishment of a continuous line of macrophages, then the macrophages established as a continuous line are cultured in the presence of a suitable activating substance and the supernatant liquid is collected from these cultures. This supernatant contains substances inhibiting the proliferation of the cells having a rapid rate of multiplication. This supernatant liquid is, if necessary, subjected to a purification process. The product is notably useful for inhibiting human tumor cells.
Inventors
- 👤 Jean Choay
- 👤 Paul Trolard
- 👤 Henri Lucien Febvre
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 09:53
CPC Classifications
A; A61; A61K; A61K35/00; A61K35/12; A61K35/14; A61K35/15
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
118 words
A process for obtaining from human macrophages, a new product inhibiting the abnormal multiplication of human tumor cells, said process comprising: isolating macrophages by the in vitro action on human macrophages, swabbed in situ from human cells, of a macrophage activating agent which causes the removal by the macrophages of the other cells present in the swabbed cellular medium; placing the macrophages thus isolated in a suitable culture medium until the establishment of a continuous line of macrophages; culturing the macrophages established as a continuous line, in the presence of a macrophage activating agent; and collecting the supernatant liquid from these cultures, which supernatant contains substances inhibiting the proliferation of the cells having a rapid rate of multiplication.
Claim 2
Dependent Claim
118 words
A process for obtaining from human macrophages, a new product inhibiting the abnormal multiplication of human tumor cells, said process comprising: isolating macrophages by the in vitro action on human macrophages, swabbed in situ from human cells, of a macrophage activating agent which causes the removal by the macrophages of the other cells present in the swabbed cellular medium; placing the macrophages thus isolated in a suitable culture medium until the establishment of a continuous line of macrophages; culturing the macrophages established as a continuous line, in the presence of a macrophage activating agent; and collecting the supernatant liquid from these cultures, which supernatant contains substances inhibiting the proliferation of the cells having a rapid rate of multiplication.
Claim 3
Dependent Claim
55 words
Process according to claim 1, wherein the macrophages isolated selectively from the other cells present in the medium by means of an activating agent, are subjected to the combined action of trypsin and of a chelating agent for the Ca ++ and Mg ++ ions to thereby prevent the adherence of macrophages to support surfaces.
Claim 4
Dependent Claim
23 words
Process according to claim 2, wherein the trypsinisation and Ca ++ and Mg ++ chelation treatment is preceded by a preliminary trypsinisation operation.
Claim 5
Dependent Claim
40 words
Process according to claim 1, wherein the macrophages are established in continuous lines by successive subcultures using a reactivation process by the introduction of fresh amounts of activating agent in the course of at least one of the successive subcultures.
Claim 6
Dependent Claim
48 words
Process according to claim 1, wherein the activating agent applied to produce selective isolation of the macrophages from the cellular swab medium, and the activating agent applied in the culturing of the cell culture established as a continuous line to obtain the active supernatant liquid are the same.
Claim 7
Dependent Claim
18 words
Process according to claim 1, wherein the activating agent applied in the culture medium is tumoral ascites liquid.
Claim 8
Dependent Claim
24 words
Process according to claim 1, wherein the activating agent applied in the culture medium is a bicatenary polynucleotide or a mixture of bicatenary polynucleotides.
Claim 9
Dependent Claim
21 words
Process according to claim 1, wherein the activating agent applied in the culture medium comprises mycobacteria, or corynebacteria or their fractions.
Claim 10
Dependent Claim
22 words
Process according to claim 1, wherein the activating agent applied in the culture medium is a culture of lymphocytes B or T.
Claim 11
Dependent Claim
20 words
Process according to claim 1, wherein the activating agent applied in the culture medium is supernatant liquid of lymphocyte cultures.
Claim 12
Dependent Claim
40 words
Process according to claim 2, wherein the macrophages are established in continuous lines by successive subcultures using a reactivation process by the introduction of fresh amounts of activating agent in the course of at least one of the successive subcultures.
Claim 13
Dependent Claim
39 words
New product active as an agent for inhibiting the abnormal multiplication of cells, obtained by applying the process according to claim 1, which product may be used as a laboratory reagent, or as a material for preparing therapeutic products.
Claim 14
Dependent Claim
23 words
A process in accordance with claim 1 wherein the human macrophages are obtained from carcinoma tumors, from ascites liquid or from embryonic organs.
Claim 15
Dependent Claim
13 words
A process in accordance with claim 1 further comprising purifying said supernatant liquid.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-12-19 | 1981-06-20 | 1981-12-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-12-19 | 1985-06-20 | 1985-12-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-12-19 | 1989-06-20 | 1989-12-20 | $7700.00 | Window Closed / Lapsed |